

Seasonal Affective Disorder: A Clinical Update

ÅSA WESTRIN, MD, PHD

Department of Clinical Sciences, Division of Psychiatry, Lund University Hospital, Lund, Sweden

RAYMOND W. LAM, MD, FRCPC

Division of Clinical Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

Background. Seasonal affective disorder (SAD) consists of recurrent major depressive episodes in the fall/winter with remissions in spring/summer.

Method. A Medline search was conducted to identify studies relating to clinical management of SAD using the Medical Subject Heading, seasonal affective disorder, and key words, depress* and season*, focusing on studies published in the past 10 years. The Cochrane library of systematic reviews was also searched for relevant studies.

Results. A careful history is important to make the diagnosis and differentiate SAD from other similar conditions such as subsyndromal SAD and atypical depression. Seasonal patterns with winter worsening are also recognized in "nonseasonal" depression as well as many other psychiatric conditions, and comorbidity with SAD is common. The pathophysiology of SAD seems to be heterogeneous as research on circadian, neurotransmitter function and genetic hypotheses have shown discrepant results. A dual vulnerability model with differential loading on separate seasonal and depression factors has been proposed to explain these findings. Recent systematic reviews have shown that light therapy is an efficacious and well-tolerated treatment for SAD. There is also evidence for efficacy of pharmacotherapy to treat and prevent SAD. Clinical studies show equal effectiveness with light and antidepressants, so patient preference should be considered in the selection of initial treatment. Dawn stimulation, negative air ions, exercise and cognitive behaviour therapy are under investigation and may also be helpful treatments for SAD.

Conclusions. SAD is a common condition with significant psychosocial impairment. Clinicians should be vigilant in recognizing seasonal patterns of depressive episodes because there are effective, evidence-based treatments for SAD.

Keywords Seasonal affective disorder, Depression, Light, Seasons, Diagnosis

INTRODUCTION

The identification of seasonal patterns for mood disturbances dates back to ancient times, with astute medical observers such as Hippocrates, Pinel, and Kraepelin reporting clear recurrent winter depressive episodes in some of their patients (1). The first systematic description of seasonal affective disorder (SAD) in 1984 (2) led to the development of bright, artificial light, or light therapy, as a treatment. In the past two decades, the concept of SAD has captured media and public interest, while at the same time provoking some skepticism amongst some in the medical community. Recent systematic reviews have demonstrated that light therapy is a safe, well-tolerated and effective treatment for winter

depression, but advances in chronobiology and genetics have suggested that the pathophysiology of SAD and the mechanism of light therapy may be more complex than previously thought.

For this review, we identified relevant clinical studies of SAD by conducting an electronic search on Medline using the Medical Subject Heading, seasonal affective disorder, and the key words, depress* and season*. We also searched the Cochrane library of systematic reviews for relevant studies. In this article, we focus on recent findings within the past 10 years and their importance to the clinical management of SAD.

DIAGNOSIS

The first criteria for the diagnosis of winter SAD were described by Rosenthal and colleagues (2). The diagnostic criteria have since been revised and narrowed but they have basically remained the

Address correspondence to Dr. Raymond W. Lam, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, B.C., Canada V6T 2A1. E-mail: r.lam@ubc.ca

Table 1 DSM-IV Criteria for Seasonal Pattern of Major Depressive Disorder (Recurrent Major Depressive Disorder, Bipolar I Disorder or Bipolar II Disorder)

-
- A. There has been a regular temporal relationship between the onset of major depressive episodes and a particular time of the year.
- B. Full remissions (or change from depression to mania or hypomania) also occur at a characteristic time of the year.
- C. In the last two years, two major depressive episodes have occurred that demonstrate the temporal seasonal relationships defined in criteria A and B, and no nonseasonal major depressive episodes have occurred during the same period.
- D. Seasonal major depressive episodes (as described above) substantially outnumber the nonseasonal major depressive episodes that may have occurred over the individual's lifetime.
-

same: a regular temporal relationship between the onset of major depressive episodes during the fall/winter period, and an occurrence of full remission (or change from depression to mania or hypomania) of symptoms during the spring/summer period.

In DSM-IV, SAD is defined as a specifier of recurrent major depressive episodes (Table 1). This seasonal pattern specifier can be applied to recurrent major depressive disorder (MDD) or to bipolar I or II disorder. Some patients with SAD may experience nonseasonal depressive episodes (e.g., a winter episode that extends into the summer months) during their lifetime, but these must be substantially less common than the seasonal episodes. The DSM-IV criteria also require that the last two seasonal depressive episodes occur in consecutive winters, but this criterion is controversial because it is not evidence-based. Other explanations for seasonal patterns of depressive episodes, such as regularly recurring psychosocial stressors such as winter unemployment and holidays, must be ruled out.

To diagnose SAD, it is important to carefully determine the time of onset and offset of previous depressive episodes, and to ensure that patients have full remission in summer. Many patients with nonseasonal depressions (including dysthymia and chronic MDD) may experience winter worsening of their symptoms, but they can be differentiated from those with SAD because they are still symptomatic in the summer. Up to 20% of patients with SAD will have bipolar I or II disorder (3), so it is also important to identify spring or summer hypomania/mania. A follow-up reassessment in summer can help to identify these bipolar patients, as they may not retrospectively recognize hypomanic symptoms.

SAD versus Seasonality

There is some debate as to whether SAD is a categorical diagnosis or an extreme form of a dimensional seasonality trait. Some people have marked symptoms (especially the vegetative symptoms described below) during the winter, but not to the point where they meet criteria for MDD, or what is termed "subsyndromal" SAD (4). People with subsyndromal SAD may still experience significant distress and impairment of function (5), and they may also respond to the same treatments as SAD (6).

One of the difficulties in making the diagnosis of SAD is that the diagnosis rests on the patient's retrospective history. Despite the presence of physical symptoms, medical examination and laboratory studies are routinely normal in SAD. A helpful clinical characteristic of SAD is a positive mood response to increased (usually outdoor) light exposure and to winter travel to more southerly latitudes. Collateral information from family and/or friends may also help with diagnosis. A prospective spring/summer evaluation for hypomania is very informative in supporting a bipolar diagnosis.

Symptom Profile

Patients with SAD may suffer from general symptoms of depression including diminished pleasure or interest, psychomotor agitation or retardation, loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to think or concentrate, indecisiveness, or recurrent thoughts of death. A somatic symptom such as pain is often the presenting complaint at visits to general practice.

The majority of SAD patients report at least one of the "atypical" depressive symptoms associated with SAD such as fatigue, hypersomnia, increased appetite and weight gain, although some patients report reduced appetite, insomnia and weight loss. The increased appetite is typified by carbohydrate craving for sugars and starches that is often described as uncontrollable. Binge type eating can occur, although purging behaviors are uncommon. The increased eating and reduced activity usually leads to significant weight gain. With initial winter episodes patients lose the weight during the summer months when their appetite returns to normal and they are more active. However, with increasing age it becomes more difficult to shed the winter weight gain and there is a gradual year round increase in weight.

The presence of these atypical features has led some investigators to suggest that SAD may be a form of atypical depression, another episode specifier that is characterized by mood reactivity, a marked but temporary improvement in mood in response to favorable external circumstances. However, studies have shown that patients with SAD do not have higher rates of mood reactivity, leaden paralysis or rejection sensitivity than do nonseasonal depressed patients (7). Therefore the overlap between the two subtypes appears to be limited to the atypical vegetative symptoms. Of interest is that these atypical symptoms, particularly the overeating, predict good response to light therapy (8).

Differential Diagnosis

The differential diagnosis of SAD is similar to that of MDD in general. Physical illnesses such as hypothyroidism need to be ruled out, as do other conditions such as phase delayed sleep disorder and anniversary grief reactions. Mixed conditions and

comorbidity should be considered, especially since seasonal patterns are becoming increasingly recognized in other psychiatric conditions including bulimia nervosa, premenstrual depressive disorder, panic disorder, obsessive compulsive disorder, post traumatic stress disorder and attention deficit hyperactivity disorder (9–11). The lifetime prevalence of anxiety disorder (generalized anxiety disorder, simple phobia, social phobia) in patients with SAD is also high, though perhaps not different from that seen in nonseasonal MDD (12). Furthermore, premenstrual depressive disorder has been reported to be much more common in SAD patients than in comparison subjects (13).

EPIDEMIOLOGY

Many epidemiological studies have reported prevalence rates for SAD as high as 10% (14), but most of these studies were not conducted in general population samples and were based on the Seasonal Pattern Assessment Questionnaire (SPAQ), a retrospective self-report questionnaire that assesses seasonality rather than the diagnosis of SAD (15). The more rigorous studies of large community samples using diagnostic interviews and DSM criteria have found prevalence rates for SAD of 0.4% in the United States (16) and 1.7% to 2.9% in Canada (17;18). SAD appears linked to photoperiod (the light/dark cycle) since the prevalence of SAD is correlated with latitude (i.e., more northerly latitudes have shorter winter days) (19) but not to other environmental factors such as temperature, sunshine hours, cloud cover, snowfall, etc., especially in North American studies (for reviews, see (14,20))

ETIOLOGY

The major theories explaining the pathophysiology of SAD have recently been reviewed (21,22) and include circadian, neurotransmitter function, and genetic hypotheses. The most prominent of the circadian rhythm hypotheses is the phase shift hypothesis (23), which suggests that SAD is associated with an abnormal phase delay of the internal circadian rhythms relative to the external clock. In this hypothesis, light therapy timed in the morning would exert a corrective phase-advance of circadian rhythms. Support for the phase-shift hypothesis includes recent studies suggesting an optimal circadian timing for light therapy (24) and beneficial effects of circadian phase-shifting doses of melatonin in patients with SAD (25). However, studies using rigorous methodologies for examining circadian rhythms have not found evidence for circadian dysregulation in patients with SAD (22) and many treatment studies have not found correlation of therapeutic response with circadian phase-shifts following treatment (e.g., (26)).

Research examining the monoamine hypothesis has focused on serotonin as there is clear seasonal variation in brain and peripheral serotonin in healthy people, e.g., serotonin turnover

and hypothalamic serotonin transporter sites are lower in winter than in summer (27,28). Several studies show that tryptophan depletion can reverse the antidepressant effect of light therapy, suggesting that the therapeutic effect of light involves a serotonergic mechanism (29,30). However, other reports implicate catecholamines in the pathogenesis of SAD, e.g., retinal light sensitivity (which is dependent on retinal dopamine function) is lower in SAD patients than in healthy controls (31) and catecholamine depletion can also reverse the effects of light therapy (32).

Genetic studies have also focused on monoamine-related genes in SAD and seasonality. Promising candidate genes include 5-HT_{2A} (33–35), 5-HT_{2C} (36) and the dopamine-4 receptor (DRD4) (37). G protein (38,39) and clock-related genes (40) have also been investigated. However, these small-sample association studies are at risk for false-positive results, and as yet there are few replicated findings in the field.

These discrepant results are likely related to heterogeneity in the pathophysiology of SAD and may be explained by a dual vulnerability model that was first proposed by Young et al. (41) and subsequently expanded upon by Lam et al. (6). According to this hypothesis, seasonality and SAD may be phenotypically expressed via differential loading on separate seasonal and depression factors with different mechanisms. For example, the seasonal factor may have a circadian mechanism while the depression factor may be related to monoamine dysregulation. Alternatively, the depression factor may reflect psychological vulnerability (41), such as neuroticism. A recent study (42) suggested that vulnerability to distress symptoms in response to seasonal physiological changes is associated with neuroticism, so that individuals with high levels of seasonality but too high of a loading on the depression factor (neuroticism) may not show a pattern of SAD because their higher level of vulnerability to distress may manifest as non-seasonal depressive episodes.

TREATMENT

Light Therapy

Although light treatment for SAD is closely intertwined with the original description of the syndrome, its efficacy has been questioned. There have been dozens of positive efficacy studies of light therapy, but the results are clouded by methodological weaknesses in study designs. For example, there has been a lack of an accepted standard for adequate dosing of light treatment and for credible placebo conditions.

However, two recent systematic reviews have rigorously addressed the efficacy question. The first used Cochrane Collaboration methodology to review 14 randomized controlled trials (RCTs) of light therapy versus control conditions (43). The second was commissioned by the Council on Research of the American Psychiatric Association (APA) (44). The authors identified 50 RCTs, of which eight studies meeting strict methodological criteria were included in the meta-analysis. Both

meta-analyses found that bright light was superior to credible control conditions, with an odds ratio of 2.83 (indicating almost 3 times better odds of achieving response with light therapy) and an effect size of 0.83 (indicating a medium to large treatment effect), respectively. These results show that the therapeutic effects of light therapy are equal to, or larger than, those found in most antidepressant pharmacotherapy trials.

In clinical practice the preferred device for light therapy is the fluorescent light box that produces light intensities of greater than 2,500 lux. Lux is a unit of illumination intensity that corrects for the photopic spectral sensitivity of the human eye. For comparison, indoor evening room light is usually less than 100 lux while a brightly lit office is less than 500 lux. In contrast, outdoor light is much brighter: a cloudy grey winter day is around 4,000 lux and a sunny day can be 50,000 to 100,000 lux or more. Newer light devices under investigation use light-emitting diodes (LEDs) that allow much smaller and more portable fixtures.

Table 2 summarizes a standard protocol for light therapy that is recommended in clinical practice guidelines (45) and that in naturalistic clinical use has resulted in response rates of 65% or higher (6). Patients should be instructed to properly position themselves and maintain a correct distance to the light source. They have to be awake with their eyes open during light exposure, but they are not required to look directly at the light source, i.e., they can read or eat during the light treatment. The standard "dose" of light is 10,000 lux for 30 minutes per day. There appears to be a relationship between intensity and duration of exposure, so that light boxes rated at 2,500 lux require 2 hours of daily exposure for the same response. Light therapy is usually administered in the early morning as soon as possible upon arising, e.g., at 7:00 am or earlier, because most studies and meta-analyses have found that early morning exposure is superior to other times of the day (46).

The onset of action of light therapy is usually rapid with significant clinical improvement found in studies of 1 or 2 weeks' duration. However, individual patients may require 2–3 weeks to show clear responses to light therapy. When light therapy is discontinued, most patients will relapse after a similar period of a couple of weeks. Patients are therefore advised to use light therapy regularly during their symptomatic winter season until the time of their usual spring summer remission. Once patients have remitted they can often experiment with individual dosing

Table 2 Bright Light Therapy: Summary of Method

- 10,000 lux white, fluorescent light; no ultraviolet wavelengths
- 30 minutes/day in the early morning, upon arising
- Stay awake, with eyes open; not necessary to stare at the light, so may eat and/or read
- Determine response after 2–3 weeks
- After remission, individualize dosing during the rest of the winter season
- Initiate treatment in early autumn in following years to avoid relapses
- In patients with retinal risk factors, obtain baseline eye examinations and monitor during treatment
- In patients with bipolar I disorder, maintain on a mood stabilizer

required to stay well. Thus, they may be able to maintain their response while reducing the daily time of exposure to 15 or 20 minutes, or by using the light box on weekdays only. In subsequent years, patients may need to begin light treatments in the early autumn before the onset of symptoms to avoid any gradual impairment of function (47).

Side effects to light therapy are generally mild and transient and include headache, nausea, eyestrain, blurred vision and agitation (Table 3) (46). Bright light exposure in the later evening may also interrupt onset and maintenance of sleep. As

Table 3 Reported Adverse Effects of Light Therapy (10,000 Lux Fluorescent Light Box, 30 Minutes/Day) for SAD. Only Side Effects Reported in More Than 5% of Treated Patients Are Shown

Study:	Kogan & Guilford, 1998 (62)	Terman & Terman, 1999*(63)	Lam et al. 2006*(57)
Length of treatment	4 to 10 days, N = 70	10 to 14 days, N = 83	8 weeks, N = 48
Emergent Side Effect	%	%	%
<i>Gastrointestinal</i>			
Abdominal discomfort/pain		10	6
Nausea/vomiting	7	16	4
Diarrhea		13	4
Constipation		2	8
<i>Appetite/weight</i>			
Decreased appetite		19	15
Increased appetite		15	8
Weight loss		19	2
Weight gain		10	
<i>Central nervous system</i>			
Headache	21	8	17
Fatigue/weakness	6	3	8–17
Increased sleep		9	13
Decreased sleep		7–14	23
Overactive/excited/agitated	6	9–10	
Anxiety	3	5	13
<i>Sexual dysfunction</i>			
Decreased sexual interest		7	15
Increased sexual interest		18	
Difficulties with orgasm		6	
Difficulties with erection		5	5
<i>Eyes/Ear/Nose/Throat</i>			
Eye or vision problem	19	4–6	
Mouth sores		8	
Nasal congestion		12	
Dry mouth/throat		4–8	19
<i>Chest</i>			
Shortness of breath		6	
Coughing		15	
Breast tenderness		6	
<i>Other</i>			
Muscle/bone/joint pain		8	13
Fever/chills		7	
Sweating/Flushing			6
Feeling faint			6

*Unlike most clinical trials that depend on spontaneous patient reports, these studies used systematic questionnaires to detect treatment-emergent adverse events.

with any effective antidepressant, light therapy carries a risk for precipitating hypomanic or manic episodes in susceptible individuals. Therefore, patients with bipolar I disorder (with manic episodes) should be on mood-stabilizing medications if light therapy is used.

There are no absolute contraindications to light therapy (although retinopathies are a relative contraindication) and no evidence that light therapy is associated with ocular or retinal damage with current dosing guidelines (48). However, caution should be applied when treating patients at higher theoretical risk for bright light-induced eye toxicity (49). This includes patients with pre existing retinal disease (such as retinitis pigmentosa) or systemic illnesses that involve the retinal (such as diabetes), and those taking photosensitizing medications (such as lithium, phenothiazine antipsychotics, melatonin, and St. John's wort). For these higher-risk patients, an ophthalmologic examination is recommended before starting light therapy as well as regular follow-up exams.

Some hospitals and outpatient clinics in Europe have designed light therapy rooms for patient use, but as most clinical studies use home treatment, which is much more convenient for patients, the necessity of light therapy rooms is not clear. Many web sites now offer helpful advice and resource materials for the clinical use of light (e.g., UBCsad.ca, SLTBR.org, CET.org).

Pharmacotherapy

There have been fewer RCTs on pharmacotherapy for SAD (Table 4). Selective serotonin reuptake inhibitors (SSRIs), especially fluoxetine (20 mg/day, (50) and sertraline (50–200 mg/day, (51)), have the best evidence for efficacy, but likely

other antidepressants are also efficacious for acute treatment. A large clinical trial also found that citalopram (20–40 mg/day) was superior to placebo in preventing relapse after one week of treatment with light therapy (52).

In the only antidepressant prevention trial to date, patients with a history of SAD (N = 1042) were randomized to bupropion-XL (300 mg/day) or placebo starting early in autumn and followed throughout the winter (53). Recurrence of winter depressive episodes was significantly lower in the bupropion group (15.7% vs. 28%, respectively). However, it should be noted that the recurrence rate of SAD in this study was low overall, even in the placebo-treated group.

Open-label studies suggest that other medications may also be beneficial in SAD. These include antidepressants such as reboxetine, a selective inhibitor of noradrenaline reuptake (54), and moclobemide, a reversible inhibitor of monoamine oxidase A (55). The wake-promoting agent, modafinil, was also reported to significantly reduce fatigue in patients with SAD (56).

Light versus Antidepressants

One criticism of light therapy research has been the lack of comparisons with antidepressant medications. A recent study directly compared the two treatments in a “double-dummy” design, in which patients with SAD (N = 96) were randomly assigned to 8 weeks of double-blind treatment with either 10,000 lux (active) light treatment plus a placebo capsule, or 100-lux (placebo) light treatment and fluoxetine, 20 mg/day (57). Both groups improved during the 8 weeks with no significant differences between the two in reduction of depression

Table 4 Studies on Pharmacotherapy of SAD. Statistically Significant Differences in Efficacy are Indicated by “>”

Antidepressant(s)	Study design (N = number of patients)	Outcome	Authors
Fluoxetine	vs. placebo, RCT, 5 weeks, N = 68	• Fluoxetine = placebo in reducing depression scores • Fluoxetine > placebo in response rates	Lam et al. (50)
	vs. moclobemide, RCT, 6 weeks, N = 32	• Fluoxetine = moclobemide in reducing depression scores and in remission rates	Partonen and Lönnquist (64)
	vs. bright light, RCT, 8 weeks, N = 96	• Fluoxetine = light therapy in reducing depression scores and in response rates	Lam et al. (57)
	vs. bright light, RCT, 5 weeks, N = 40	• Fluoxetine = light therapy in reducing depression scores • Trend to superiority of fluoxetine in response rates	Ruhrmann et al. (65)
Sertraline	vs. placebo, RCT, 8 weeks, N = 187	• Sertraline > placebo in reducing depression scores and in response rates	Moscovitch et al. (51)
Citalopram	vs. placebo, RCT, 15 weeks, N = 282	• Following 1 week of successful light therapy, citalopram > placebo in preventing relapse	Martiny et al. (52)
Bupropion	vs. placebo, prevention RCT, N = 1042	• Bupropion > placebo in preventing seasonal depressive episode	Modell et al (66)
Bupropion, desipramine, tranylcypromine	Case series, open-label treatment, N = 47	• Improvement with all antidepressants	Dilsaver et al. (67)
Reboxetine	Case series, open-label treatment, N = 16	• Improvement with reboxetine	Hilger et al. (54)
Moclobemide	vs. placebo, RCT, 3 weeks, N = 34	• Moclobemide = placebo in reducing depression scores, but > placebo in reducing atypical symptoms	Lingjaerde et al. (55)
Hypericum (St. John's wort)	vs. light therapy, RCT, 4 weeks, N = 20	• Hypericum = hypericum+bright light in reducing depression scores	Martinez et al. (68)
Modafinil	Case series, open-label treatment, N = 13	• Improvement with modafinil	Lundt (56)

scores, clinical response rates (67% for both groups) or remission rates (50% for light treatment and 54% for fluoxetine). Light therapy showed earlier onset of response (at 1 week) and lower rates of some adverse events (agitation, sleep disturbance and palpitations) relative to fluoxetine, but both treatments were well-tolerated overall. In the subgroup of patients with greater severity of depression at baseline, there were again no differences in the efficacy or response/remission rates between light and fluoxetine.

These findings suggest that other factors, including patient preference, should be used to guide decisions about light or drugs as first-choice treatment. And, although there are as yet limited data on the combination, many patients with SAD use both light and antidepressant medication for optimal benefit.

Other Treatments

In addition to bright light and pharmacotherapy, other treatments under investigation may be beneficial for SAD. These include dawn simulation, negative air ionization, exercise and cognitive behaviour therapy (CBT).

Dawn simulation imitates the natural summer dawn signal by gradually increasing ambient bedroom illumination while the patient is sleeping. An electronic dawn simulation device controls a bedside lamp that turns on about 90 minutes before the desired wake time and reaches a final illumination of 250 lux, which continues until the patient arises. In the systematic review by the APA, five dawn simulation studies included in a meta-analysis showed a medium-to-large effect size of 0.73 favoring dawn simulation over placebo conditions (44). However, the total number of patients in the meta-analysis was small and the positive results came from one centre, so these results need further replication.

Negative air ionization is a new treatment and the mechanism of action is still poorly understood. In patients with SAD (N = 158), the antidepressant effects of high-density negative ions were not significantly different from those of bright light (58); therapeutic effects have also been observed in patients with chronic (nonseasonal) depression (59). Another study compared the effects of physical exercise and bright light in age-matched groups of female patients (60). The women with winter depression (N = 27) responded equally well to both exercising and light, while exercising was superior to light in patients with nonseasonal depression (N = 18).

A 6-week pilot study of 23 patients with SAD compared a standard light therapy protocol, a novel, SAD-tailored, group CBT intervention, and the combination (61). All conditions demonstrated significant but similar reductions in depressive symptoms and good remission rates. However, during the subsequent winter naturalistic follow-up, patients who had CBT, particularly in combination with light therapy, had better outcomes as measured by symptom severity, remission rates, and relapse rates.

CONCLUSIONS

The diagnosis of SAD can be made by taking a careful history of recurrent winter depressive episodes and ruling out other diagnoses. Although the etiology and pathogenesis of SAD remain unclear, the high prevalence of SAD (0.4% to 2.9%) makes it a significant health problem, particularly in northern countries. Light therapy is an evidence-based, effective, well-tolerated treatment for SAD, while antidepressant medications also have demonstrated efficacy. For many patients, the choice of light or drug (or the combination) will depend on personal preference. Research in progress on newer treatments, including smaller and more efficient light devices, dawn simulation, negative ions, exercise, and CBT, may expand the options for people with winter depression.

REFERENCES

1. Wehr TA: Seasonal affective disorders: A historical overview. In Rosenthal NE, Blehar MC (eds): *Seasonal Affective Disorders and Phototherapy* 1989; New York, Guilford Press, 11–32
2. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA: Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy. *Arch Gen Psychiatry* 1984; 41:72–80
3. White DM, Lewy AJ, Sack RL, Blood ML, Wesche DL: Is winter depression a bipolar disorder? *Compr Psychiatry* 1990; 31:196–204
4. Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE: Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. *Arch Gen Psychiatry* 1989; 46:823–833
5. Schlager D, Froom J, Jaffe A: Winter depression and functional impairment among ambulatory primary care patients. *Compr Psychiatry* 1995; 36:18–24
6. Lam RW, Tam EM, Yatham LN, Shiah IS, Zis AP: Seasonal depression: The dual vulnerability hypothesis revisited. *J Affect Disord* 2001; 63:123–132
7. Tam EM, Lam RW, Robertson HA, Stewart JN, Yatham LN, Zis AP: Atypical depressive symptoms in seasonal and non-seasonal mood disorders. *J Affect Disord* 1997; 44:39–44
8. Terman M, Amira L, Terman JS, Ross DC: Predictors of response and nonresponse to light treatment for winter depression. *Am J Psychiatry* 1996; 153:1423–1429
9. Amons PJ, Kooij JJ, Haffmans PM, Hoffman TO, Hoencamp E: Seasonality of mood disorders in adults with lifetime attention-deficit/hyperactivity disorder (ADHD). *J Affect Disord* 2006; 91:251–255
10. Ohtani T, Kaiya H, Utsumi T, Inoue K, Kato N, Sasaki T: Sensitivity to seasonal changes in panic disorder patients. *Psychiatry Clin Neurosci* 2006; 60:379–383
11. Lam RW, Goldner EM: Seasonality of bulimia nervosa and treatment with light therapy. In Lam RW (ed): *Seasonal Affective Disorder and Beyond Light Treatment for SAD and non-SAD Conditions*. Washington, DC; American Psychiatric Press, Inc., 1998. pp:193–220

12. Levitt AJ, Joffe RT, Brecher D, MacDonald C: Anxiety disorders and anxiety symptoms in a clinic sample of seasonal and non-seasonal depressives. *J Affect Disord* 1993; 28:51–56
13. Praschak-Rieder N, Willeit M, Neumeister A, Hilger E, Stastny J, Thierry N, Lenzinger E, Kasper S: Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. *J Affect Disord* 2001; 63:239–242
14. Magnusson A, Partonen T: The diagnosis, symptomatology, and epidemiology of seasonal affective disorder. *CNS Spectr* 2005; 10:625–634
15. Mersch PP, Vastenburger NC, Meesters Y, Bouhuys AL, Beersma DG, Van den Hoofdakker RH, den Boer JA: The reliability and validity of the Seasonal Pattern Assessment Questionnaire: A comparison between patient groups. *J Affect Disord* 2004; 80:209–219
16. Blazer DG, Kessler RC, Swartz MS: Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. *Br J Psychiatry* 1998; 172:164–167
17. Levitt AJ, Boyle MH, Joffe RT, Bauml Z: Estimated prevalence of the seasonal subtype of major depression in a Canadian community sample. *Can J Psychiatry* 2000; 45:650–654
18. Levitt AJ, Boyle MH: The impact of latitude on the prevalence of seasonal depression. *Can J Psychiatry* 2002; 47:361–367
19. Michalak EE, Lam RW: Seasonal affective disorder: the latitude hypothesis revisited. *Can J Psychiatry* 2002; 47:787–788
20. Magnusson A: An overview of epidemiological studies on seasonal affective disorder. *Acta Psychiatr Scand* 2000; 101:176–184
21. Sohn CH, Lam RW: Update on the biology of seasonal affective disorder. *CNS Spectr* 2005; 10:635–646
22. Lam RW, Levitan RD: Pathophysiology of seasonal affective disorder: A review. *J Psychiatry Neurosci* 2000; 25:469–480
23. Lewy AJ, Sack RL, Miller LS, Hoban TM: Antidepressant and circadian phase-shifting effects of light. *Science* 1987; 235:352–354
24. Terman JS, Terman M, Lo ES, Cooper TB: Circadian time of morning light administration and therapeutic response in winter depression. *Arch Gen Psychiatry* 2001; 58:69–75
25. Lewy AJ, Lefler BJ, Emens JS, Bauer VK: The circadian basis of winter depression. *Proc Natl Acad Sci* 2006; 103:7414–7419
26. Murray G, Michalak EE, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Lam RW: O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep. *J Affect Disord* 2006; 90:227–231
27. Lambert GW, Reid C, Kaye DM, Jennings GL, Esler MD: Effect of sunlight and season on serotonin turnover in the brain. *Lancet* 2002; 360:1840–1842
28. Neumeister A, Pirker W, Willeit M, Praschak-Rieder N, Asenbaum S, Brucke T, Kasper S: Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropine and single photon emission computed tomography. *Biol Psychiatry* 2000; 47:158–160
29. Lam RW, Zis AP, Grewal A, Delgado PL, Charney DS, Krystal JH: Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. *Arch Gen Psychiatry* 1996; 53:41–44
30. Neumeister A, Praschak-Rieder N, Besselmann B, Rao ML, Gluck J, Kasper S: Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. *Arch Gen Psychiatry* 1997; 54:133–138
31. Hebert M, Beattie CW, Tam EM, Yatham LN, Lam RW: Electretroretinography in patients with winter seasonal affective disorder. *Psychiatry Res* 2004; 127:27–34
32. Lam RW, Tam EM, Grewal A, Yatham LN: Effects of alpha-methyl-para-tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission. *Neuropsychopharmacology* 2001; 25:S97–101
33. Arias B, Gutierrez B, Pintor L, Gasto C, Fananas L: Variability in the 5-HT(2A) receptor gene is associated with seasonal pattern in major depression. *Mol Psychiatry* 2001; 6:239–242
34. Enoch MA, Goldman D, Barnett R, Sher L, Mazzanti CM, Rosenthal NE: Association between seasonal affective disorder and the 5-HT2A promoter polymorphism, -1438G/A. *Mol Psychiatry* 1999; 4:89–92
35. Lee HJ, Sung SM, Lim SW, Paik JW, Leen K: Seasonality associated with the serotonin 2A receptor -1438 A/G polymorphism. *J Affect Disord* 2006; 96:145–148
36. Praschak-Rieder N, Willeit M, Zill P, Winkler D, Thierry N, Konstantinidis A, Masellis M, Basile VS, Bondy B, Ackenheil M, Neumeister A, Kaplan AS, Kennedy JL, Kasper S, Levitan R: A Cys23-Ser23 substitution in the 5-HT(2C) receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian-Canadian collaborative study. *J Psychiatr Res* 2005; 39:561–567
37. Levitan RD, Masellis M, Basile VS, Lam RW, Kaplan AS, Davis C, Muglia P, Mackenzie B, Tharmalingam S, Kennedy SH, Macciardi F, Kennedy JL: The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. *Biol Psychiatry* 2004; 56:665–669
38. Willeit M, Praschak-Rieder N, Zill P, Neumeister A, Ackenheil M, Kasper S, Bondy B: C825T polymorphism in the G protein beta3-subunit gene is associated with seasonal affective disorder. *Biol Psychiatry* 2003; 54:682–686
39. Johansson C, Willeit M, Aron L, Smedh C, Ekholm J, Paunio T, Kiesepa T, Lichtermann D, Praschak-Rieder N, Neumeister A, Kasper S, Peltonen L, Adolfsson R, Partonen T, Schalling M: Seasonal affective disorder and the G-protein beta-3-subunit C825T polymorphism. *Biol Psychiatry* 2004; 55:317–319
40. Johansson C, Willeit M, Smedh C, Ekholm J, Paunio T, Kiesepa T, Lichtermann D, Praschak-Rieder N, Neumeister A, Nilsson LG, Kasper S, Peltonen L, Adolfsson R, Schalling M, Partonen T: Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. *Neuropsychopharmacology* 2003; 28:734–739
41. Young MA, Watel LG, Lahmeyer HW, Eastman CI: The temporal onset of individual symptoms in winter depression: Differentiating underlying mechanisms. *J Affect Disord* 1991; 22:191–197
42. Enns MW, Cox BJ, Levitt AJ, Levitan RD, Morehouse R, Michalak EE, Lam RW: Personality and seasonal affective disorder: Results from the CAN-SAD study. *J Affect Disord* 2006; 93:35–42
43. Thompson C: Evidence-based treatment. In Partonen T, Magnusson A (eds): *Seasonal Affective Disorder: Practice and Research*. New York: Oxford University Press, 2001, pp:151–158
44. Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB: The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. *Am J Psychiatry* 2005; 162:656–662

45. Lam RW, Levitt AJ (eds): *Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder*. Vancouver, BC: Clinical and Academic Publishing, 1999
46. Terman M, Terman JS: Light therapy for seasonal and nonseasonal depression: Efficacy, protocol, safety, and side effects. *CNS Spectr* 2005; 10:647–663
47. Partonen T, Lonnqvist J: Prevention of winter seasonal affective disorder by bright-light treatment. *Psychol Med* 1996; 26:1075–1080
48. Gallin PF, Terman M, Reme CE, Rafferty B, Terman JS, Burde RM: Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. *Am J Ophthalmol* 1995; 119:202–210
49. Reme CE, Rol P, Grothmann K, Kaase H, Terman M: Bright light therapy in focus: lamp emission spectra and ocular safety. *Technol Health Care* 1996; 4:403–413
50. Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR, Watson GD, Morehouse RL, Tam W, Joffe RT: Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. *Am J Psychiatry* 1995; 152:1765–1770
51. Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S, Lane RM: A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. *Psychopharmacology (Berl)* 2004; 171:390–397
52. Martiny K, Lunde M, Simonsen C, Clemmensen L, Poulsen DL, Solstad K, Bech P: Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. *Acta Psychiatr Scand* 2004; 109:230–234
53. Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS: Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. *Biol Psychiatry* 2005; 58:658–667
54. Hilger E, Willeit M, Praschak-Rieder N, Stastny J, Neumeister A, Kasper S: Reboxetine in seasonal affective disorder: an open trial. *Eur Neuropsychopharmacol* 2001; 11:1–5
55. Lingjaerde O, Reichborn-Kjennerud T, Haggag A, Gartner I, Narud K, Berg EM: Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. *Acta Psychiatr Scand* 1993; 88:372–380
56. Lundt L: Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. *J Affect Disord* 2004; 81:173–178
57. Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE, Tam EM: The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. *Am J Psychiatry* 2006; 163:805–812
58. Terman M, Terman JS, Ross DC: A controlled trial of timed bright light and negative air ionization for treatment of winter depression. *Arch Gen Psychiatry* 1998; 55:875–882
59. Goel N, Terman M, Terman JS, Macchi MM, Stewart JW: Controlled trial of bright light and negative air ions for chronic depression. *Psychol Med* 2005; 35:945–955
60. Pinchasov BB, Shurgaja AM, Grischin OV, Putilov AA: Mood and energy regulation in seasonal and non-seasonal depression before and after midday treatment with physical exercise or bright light. *Psychiatry Res* 2000; 94:29–42
61. Rohan KJ, Lindsey KT, Roecklein KA, Lacy TJ: Cognitive-behavioral therapy, light therapy, and their combination in treating seasonal affective disorder. *J Affect Disord* 2004; 80:273–283
62. Kogan AO, Guilford PM: Side effects of short-term 10,000-lux light therapy. *Am J Psychiatry* 1998; 155:293–294
63. Terman M, Terman JS: Bright light therapy: Side effects and benefits across the symptom spectrum. *J Clin Psychiatry* 1999; 60:799–808
64. Partonen T, Lonnqvist J: Moclobemide and fluoxetine in treatment of seasonal affective disorder. *J Affect Disord* 1996; 41:93–99
65. Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T, Moller HJ: Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. *Psychol Med* 1998; 28:923–933
66. Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS: Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. *Biol Psychiatry* 2005; 58:658–667
67. Dilsaver SC, Del M, V, Quadri A, Jaeckle S: Pharmacological responsiveness of winter depression. *Psychopharmacol Bull* 1990; 26:303–309
68. Martinez B, Kasper S, Ruhrmann S, Moller HJ: Hypericum in the treatment of seasonal affective disorders. *J Geriatr Psychiatry Neurol* 1994; 7 (Suppl 1):S29–33